Online inquiry

IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14043MR)

This product GTTS-WQ14043MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets LAG3 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002286.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3902
UniProt ID P18627
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ14043MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8418MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HSP90mab
GTTS-WQ15924MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ5931MR IVTScrip™ mRNA-Anti-CD274, CK-301(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CK-301
GTTS-WQ3556MR IVTScrip™ mRNA-Anti-MIF, BAX069(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAX069
GTTS-WQ12578MR IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA NV-02
GTTS-WQ6996MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA F-627
GTTS-WQ2073MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AH-PD1
GTTS-WQ9710MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64407564
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW